A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
ApexOnco Front Page
Recent articles
So who else could be interested in the oestrogen degrader?
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
The first data are dribbled out, but cross-trial comparisons look uninspiring.
Jazz’s Chimerix buy faces its big test.
More data from onvansertib's phase 2 study fail to convince.
NT-125 is discontinued, while two key Datroway readouts are delayed.
A Pfizer cast-off could become the company's first marketed drug.
